Tacrolimus only for breakfast ⋯

Transplant International

Volumn 25, Issue 3, 2012, Pages 274-275

  Budde, Klemens ^a   Matz, Mareen ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

conversion; drug formulation; non adherence; pharmacokinetics; tacrolimus

Indexed keywords

TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

BIOEQUIVALENCE; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG FORMULATION; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; LIVER TRANSPLANTATION; NOTE; PRIORITY JOURNAL; TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; FEMALE; MALE;

FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; TACROLIMUS;

EID: 84856921326     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2011.01422.x     Document Type: Note

References (10)

1. Saåko-Resmer J, Boillot O, Wolf P, Thorburn D,. Renal function, efficacy and safety post-conversion from twice- to once-daily tacrolimus in stable liver recipients: an open-label multicenter study. Transpl Int 2012; 25: 283.
2. Borra LC, Roodnat JI, Kal JA, Mathot RA, Weimar W, van Gelder T,. High within-patient variability in the clearance of tacrolimus is a risk factor for poor long-term outcome after kidney transplantation. Nephrol Dial Transplant 2010; 25: 2757.
3. Trunecka P, Boillot O, Seehofer D, et al. Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation. Am J Transplant 2010; 10: 2313.
4. Florman S, Alloway R, Kalayoglu M, et al. Conversion of stable liver transplant recipients from a twice-daily Prograf-based regimen to a once-daily modified release tacrolimus-based regimen. Transplant Proc 2005; 37: 1211.
5. Florman S, Alloway R, Kalayoglu M, et al. Once-daily tacrolimus extended release formulation: experience at 2 years postconversion from a Prograf-based regimen in stable liver transplant recipients. Transplantation 2007; 83: 1639.
6. Alloway R, Steinberg S, Khalil K, et al. Two years postconversion from a prograf-based regimen to a once-daily tacrolimus extended-release formulation in stable kidney transplant recipients. Transplantation 2007; 83: 1648.
7. Krämer BK, Charpentier B, Bäckman L, et al. Tacrolimus once daily (ADVAGRAF) versus twice daily (PROGRAF) in de novo renal transplantation: a randomized phase III study. Am J Transplant 2010; 10: 2632.
8. A de Jonge H, Kuypers DR, Verbeke K, Vanrenterghem Y,. Reduced C0 concentrations and increased dose requirements in renal allograft recipients converted to the novel once-daily tacrolimus formulation. Transplantation 2010; 90: 523.
9. Wehland M, Bauer S, Brakemeier S, et al. Differential impact of the CYP3A5*1 and CYP3A5*3 alleles on pre-dose concentrations of two tacrolimus formulations. Pharmacogenet Genomics 2011; 21: 179.
10. Wu MJ, Cheng CY, Chen CH, et al. Lower variability of tacrolimus trough concentration after conversion from prograf to advagraf in stable kidney transplant recipients. Transplantation 2011; 92: 648.